A Phase 1b/2, Open-Label Trial To Assess The Safety And Preliminary Efficacy Of Epcoritamab (GEN3013; Duobody®-CD3xCD20) In Combination With Other Agents In Subjects With B-Cell Non-Hodgkin Lymphoma Read more
A Phase 1, Multicenter, Open-Label Study Of Bms-986403 In Subjects With Relapsed And/Or Refractory Chronic Lymphocytic Leukemia (Cll) Or Small Lymphocytic Lymphoma (Sll) Read more
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia Read more
Long-Term Follow-Up Study For Participants Of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Read more
A Phase II Study Of Venetoclax And Rituximab/Hyaluronidase Human In Relapsed/Refractory CLL Read more
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14) Read more
A Prospective, Open-Label, Multicenter Randomized Phase III Study To Compare The Efficacy And Safety Of A Combined Regimen Of Venetoclax And Obinutuzumab Versus Fludarabine, Cyclophosphamide, And Rituximab (FCR)/Bendamustine And Rituximab (BR) In FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) Or TP53 Mutation Read more
